Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck posts higher profit, puts tariffs cost at $200 million
06:34am, Thursday, 24'th Apr 2025
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a January decision to pause shipments of its Gardasil vaccine to China d
Merck lowers profit outlook, partly due to $200 million expected tariff hit
06:32am, Thursday, 24'th Apr 2025
Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the expe
Merck Announces First-Quarter 2025 Financial Results
06:30am, Thursday, 24'th Apr 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Financial Results.
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
02:40pm, Wednesday, 23'rd Apr 2025
Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
The Setup: Chipotle, United Rentals, Merck and Pepsi
01:20pm, Wednesday, 23'rd Apr 2025
The Investment Committee give you The Setup on some key names reporting this week.
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
11:13am, Tuesday, 22'nd Apr 2025
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
10:10am, Tuesday, 22'nd Apr 2025
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
08:35am, Tuesday, 22'nd Apr 2025
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
09:33pm, Monday, 21'st Apr 2025
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I mai
Merck & Co.: Pipeline Resilience To Unlock Value
11:14am, Monday, 21'st Apr 2025
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins,
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
09:00am, Monday, 21'st Apr 2025
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:20am, Friday, 18'th Apr 2025
Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter en
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
08:47am, Friday, 18'th Apr 2025
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Merck & Co., Inc. (NYSE: MRK) o
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Thursday, 17'th Apr 2025
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
